Recently, the immune checkpoint inhibitors (ICIs), including CTLA-4 and PD-1/PD-L1 inhibitors, have become a breakthrough in cancer therapy, which has aroused great enthusiasm in tumor immunotherapy research (Llosa et al., 2015). The gene discussed is CD274; the disease is neoplasm.